See more : Gan & Lee Pharmaceuticals. (603087.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. (EDD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Morgan Stanley Emerging Markets Domestic Debt Fund, Inc., a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Shanghai Huide Science & Technology Co.,Ltd (603192.SS) Income Statement Analysis – Financial Results
- Kyushu Financial Group, Inc. (7180.T) Income Statement Analysis – Financial Results
- Crescita Therapeutics Inc. (CRRTF) Income Statement Analysis – Financial Results
- DNO ASA (DTNOY) Income Statement Analysis – Financial Results
- Sterlite Technologies Limited (STLTECH.NS) Income Statement Analysis – Financial Results
Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. (EDD)
Industry: Asset Management
Sector: Financial Services
About Morgan Stanley Emerging Markets Domestic Debt Fund, Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. is a closed ended fixed income mutual fund launched and managed by Morgan Stanley Investment Management Inc. The fund invests in fixed income markets of emerging market countries across the globe. It typically invests in government bonds denominated in the local currencies of emerging markets. The fund benchmarks the performance of its portfolio against the JPMorgan Government Bond Index - Emerging Markets Global Diversified Index. Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. was formed on January 25, 2007 and is domiciled in United States.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.67M | -84.70M | 6.53M | -26.04M | 64.94M | -56.62M | 31.89M | 55.57M | 73.12M | 89.00M | 112.30M | 122.20M | 137.40M | 134.00M | 122.70M | 192.10M | 89.20M |
| Cost of Revenue | 4.86M | 5.47M | 6.74M | 7.05M | 7.99M | 9.19M | 9.81M | 9.93M | 17.83M | 16.80M | 19.90M | 18.80M | 18.90M | 26.10M | 21.40M | 19.80M | 11.90M |
| Gross Profit | 33.81M | -90.17M | -206.00K | -33.09M | 56.95M | -65.82M | 22.08M | 45.64M | 55.29M | 72.20M | 92.40M | 103.40M | 118.50M | 107.90M | 101.30M | 172.30M | 77.30M |
| Gross Profit Ratio | 87.42% | 106.46% | -3.15% | 127.06% | 87.69% | 116.24% | 69.23% | 82.13% | 75.62% | 81.12% | 82.28% | 84.62% | 86.24% | 80.52% | 82.56% | 89.69% | 86.66% |
| Research & Development | 0.00 | 0.93 | 0.29 | -7.61 | -14.20 | -1.45 | -1.41 | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 957.00K | 940.00K | 1.09M | 1.08M | 1.22M | 1.37M | 1.69M | 100.00K | 109.00K | 200.00K | 200.00K | 1.00M | 1.50M | 1.40M | 900.00K | 300.00K | 100.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 957.00K | 940.00K | 1.09M | 1.08M | 1.22M | 1.37M | 1.69M | 0.85 | 109.00K | 200.00K | 200.00K | 1.00M | 1.50M | 1.40M | 900.00K | 300.00K | 100.00K |
| Other Expenses | 37.71M | 167.00K | 134.00K | 151.00K | 192.00K | 137.00K | -19.00K | 67.13M | 226.00K | 200.00K | 100.00K | 100.00K | 100.00K | 500.00K | 600.00K | 16.50M | 11.90M |
| Operating Expenses | 38.67M | 1.11M | 1.22M | 1.24M | 1.41M | 1.51M | 1.67M | -184.95M | 335.00K | 400.00K | 300.00K | 1.10M | 1.60M | 1.90M | 1.50M | 16.80M | 12.00M |
| Cost & Expenses | 38.67M | 1.11M | 1.22M | 1.24M | 1.41M | 1.51M | 1.67M | 45.64M | 18.16M | 17.20M | 20.20M | 19.90M | 20.50M | 28.00M | 22.90M | 36.60M | 23.90M |
| Interest Income | 28.70M | 27.54M | 29.00M | 35.11M | 49.04M | 62.44M | 58.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.93M | 2.14M | 1.72M | 3.21M | 7.34M | 7.83M | 6.19M | 4.96M | -319.48M | -153.90M | -114.80M | 8.40M | -120.00M | 154.70M | 240.70M | -540.30M | 68.00M |
| Depreciation & Amortization | 0.00 | 228.49K | 236.56K | 206.30K | 171.86K | 161.14K | 52.52K | -10.28M | -638.93M | -307.70M | -229.60M | 16.80M | -240.00M | 309.80M | 487.40M | -1.09B | 148.00M |
| EBITDA | 39.43M | -83.66M | 5.32M | -27.28M | 63.53M | -50.31M | 36.41M | 225.63M | -583.98M | -235.90M | -137.50M | 119.20M | -123.10M | 415.80M | 587.20M | -934.70M | 213.30M |
| EBITDA Ratio | 101.98% | 98.78% | 81.34% | 104.74% | 97.83% | 88.85% | 114.19% | -306.02% | -798.71% | -265.06% | -122.44% | 97.55% | -89.59% | 310.30% | 478.57% | -486.57% | 239.13% |
| Operating Income | 39.43M | -83.66M | 5.32M | -27.28M | 63.53M | -50.31M | 36.41M | 230.59M | 54.95M | 71.80M | 92.10M | 102.40M | 116.90M | 106.00M | 99.80M | 155.40M | 65.30M |
| Operating Income Ratio | 101.98% | 98.78% | 81.34% | 104.74% | 97.83% | 88.85% | 114.19% | 414.94% | 75.16% | 80.67% | 82.01% | 83.80% | 85.08% | 79.10% | 81.34% | 80.90% | 73.21% |
| Total Other Income/Expenses | -1.95M | -2.14M | 0.00 | -4.89M | 0.00 | -7.83M | -844.00K | -183.33M | -319.46M | -153.80M | -114.80M | 8.40M | -120.00M | 155.10M | 246.70M | -549.80M | 80.00M |
| Income Before Tax | 37.49M | -85.80M | 5.32M | -27.28M | 63.53M | -58.13M | 30.22M | 47.26M | -264.51M | -82.00M | -22.70M | 110.80M | -3.10M | 261.10M | 346.50M | -394.40M | 145.30M |
| Income Before Tax Ratio | 96.94% | 101.31% | 81.34% | 104.74% | 97.83% | 102.67% | 94.77% | 85.05% | -361.77% | -92.13% | -20.21% | 90.67% | -2.26% | 194.85% | 282.40% | -205.31% | 162.89% |
| Income Tax Expense | 0.00 | -80.68M | 7.27M | -22.39M | 70.87M | -161.14K | 37.26M | 230.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 37.49M | -85.80M | 5.32M | -27.28M | 63.53M | -58.13M | 30.22M | 230.59M | -264.51M | -82.00M | -22.70M | 110.80M | -3.10M | 261.10M | 346.50M | -394.40M | 145.30M |
| Net Income Ratio | 96.94% | 101.31% | 81.34% | 104.74% | 97.83% | 102.67% | 94.77% | 414.94% | -361.77% | -92.13% | -20.21% | 90.67% | -2.26% | 194.85% | 282.40% | -205.31% | 162.89% |
| EPS | 0.57 | -1.30 | 0.08 | -0.41 | 0.96 | -0.88 | 0.45 | 4.88 | -3.89 | -1.17 | -0.32 | 1.53 | -0.04 | 3.61 | 4.79 | -5.38 | 1.98 |
| EPS Diluted | 0.57 | -1.30 | 0.08 | -0.41 | 0.96 | -0.88 | 0.45 | 327.50M | -3.89 | -1.17 | -0.32 | 1.53 | -0.04 | 3.61 | 4.79 | -5.38 | 1.98 |
| Weighted Avg Shares Out | 65.26M | 65.99M | 66.09M | 66.09M | 66.18M | 66.06M | 67.13M | 47.26M | 67.96M | 69.80M | 71.30M | 72.40M | 72.40M | 72.40M | 72.40M | 73.30M | 73.30M |
| Weighted Avg Shares Out (Dil) | 65.26M | 65.99M | 66.09M | 66.09M | 66.18M | 66.06M | 67.15M | 0.70 | 67.96M | 69.80M | 71.30M | 72.40M | 72.40M | 72.40M | 72.40M | 73.30M | 73.30M |
Analyse AOF clôture Wall Street - Vent d'inquiétudes
(AOF) - Les bourses américaines ont clôturé dans le rouge jeudi,emportées par une série d'inquiétudes liées au coronavirus. D'une part, la propagation continue de l'épidémie pousse les gouvernements à
The Medibank (ASX:MPL) share price rockets on broker upgrade
The Medibank Private Ltd (ASX: MPL) share price jumped to a near two-month high this morning after a broker upgraded the stock. But it isn’t the only ASX stock that got up upgraded to “buy”.
Morgan Stanley says India stocks are 'attractive' relative to other emerging markets
The MSCI India Index is up 39.36% since mid-April compared to a 26.7% rise in the MSCI Emerging Markets Index, according to data from Refinitiv Eikon.
Het nettoresultaat van Morgan Stanley stijgt tot £2,11 miljard | Invezz
Het nettoresultaat van Morgan Stanley stijgt tot £2,11 miljard in Q3. De investeringsbank laat in het derde kwartaal een omzetgroei van 16,2% zien.
Stocks Jump Off Lows but Still Slide for a Third Day
Stocks Analysis by Zacks Investment Research covering: Citigroup Inc, Bank of America Corp, JPMorgan Chase & Co, Vertex Pharmaceuticals Inc. Read Zacks Investment Research's latest article on Investing.com
L'utile netto di Morgan Stanley sale a £2,11 miliardi nel Q3 | Invezz
La banca d'investimento rivela una crescita dei ricavi del 16,2% anno su anno nel Q3. I ricavi dall'investment banking hanno una crescita dell'11,2% nel Q3.
Value Investing Is Not Dead: An Eaton Vance Case Study (NYSE:EV)
There has been much talk about the underperformance of value stocks and whether there will at some point be a rotation into them.
The Stock Market Is Strong -- Just Look at Morgan Stanley and Schwab | The Motley Fool
Despite declines today, stocks look healthy according to the companies that rely on a healthy market.
Source: https://incomestatements.info
Category: Stock Reports